PATHOPHYSIOLOGY OF VOD/SOS

VOD/SOS can rapidly progress from endothelial damage to death1,2

Take a closer look at the cascade of events that precedes the clinical manifestations of VOD/SOS.

liver icon

Learn more about the progressive cascade of VOD/SOS from leading experts

Watch videos

Progressive cascade of VOD/SOS

Based on experimental models, buildup of toxic metabolites from HSCT conditioning regimens may trigger activation of and damage to sinusoidal endothelial cells in the liver. This can lead to a cascade of events that is potentially life-threatening.1,3-5

Hepatocytes

Hepatocytes

endothelial cell

Endothelial cells

red blood cell

Red blood cells

white blood cell

White blood cells

platelet activated

Platelets

extracellular matrix

Extracellular matrix

1 healthy sinusoid

Healthy sinusoid

  • Sinusoidal endothelial cells provide a barrier between the blood and hepatocytes and regulate hemostasis, permeability, vascular tone, and immune and inflammatory responses.6
2 endothelial damage

Endothelial damage

  • Activation of endothelial cells triggers expression of cytokines and adhesion molecules, activating inflammatory pathways that cause additional endothelial damage4,5
  • Release of the enzyme heparanase contributes to degradation of the extracellular matrix, loss of cytoskeletal structure, and gap formation between sinusoidal endothelial cells3,5
  • Degradation of the extracellular matrix leads to detachment of endothelial cells from the sinusoidal lining6,7
3 sinusoid narrowing

Sinusoidal narrowing

  • This ongoing degradation of the endothelium allows red blood cells, leukocytes, and cellular debris to move into the space of Disse3-5
  • This can lead to sinusoidal narrowing, which may lead to endothelial cells embolizing downstream and contribute to sinusoidal blockage3-5
4 sinusoid blockage

Sinusoidal blockage

  • Sinusoidal endothelial cell damage also triggers the expression of multiple factors that regulate coagulation and fibrinolysis (table A)1,4,5
  • All of these events can lead to a procoagulant and hypofibrinolytic state, where fibrin deposition, clot formation, and sinusoidal narrowing can cause further blockage1,4,5
  • Hepatocyte cell death is a consequence of sinusoidal disruption, and further sinusoidal obstruction may lead to a reduction in hepatic venous outflow and to post-sinusoidal hypertension3-6

The cascade of events appears to start before clear clinical and LABORATORY manifestations are evident.4,5,8

FACTORS THAT REGULATE COAGULATION AND FIBRINOLYSIS5,9,10

Factor
Function
von Willebrand factor
stimulates platelet aggregation
Tissue factor
promotes activation of factor X
Plasminogen activator inhibitor-1
reduces fibrinolysis

Clinical manifestations and progression of VOD/SOS

Sinusoidal obstruction may lead to a reduction in hepatic venous outflow and to post-sinusoidal hypertension, resulting in clinical signs and symptoms.3-5

Most common signs and symptoms of VOD/SOS2,3,8

  • Excessive platelet transfusions consistent with refractory thrombocytopenia
  • Weight gain due to fluid retention
  • Hepatomegaly
  • Right upper quadrant pain
  • Elevated bilirubin
  • Elevated serum transaminase and alkaline phosphatase
  • Ascites

Vigilant monitoring for the first 21 days after hsct is critical to detect VOD/SOS.2

Although VOD/SOS generally emerges within the first 21 days, it can occur later.2,11

Recognize the factors shown to greatly increase the risk of VOD/SOS in HSCT patients8,11-14

Level of Riska

Patient and Disease-
Related Risk Factors

HEPATIC-RELATED
RISK FACTORS

TRANSPLANT-RELATED
RISK FACTORS

10-20 times
greater risk

  • Prior norethindrone treatment
  • Previous inotuzumab treatment
  • Previous gemtuzumab treatment
  • Bilirubin >1.5 mg/dL

3-10 times
greater risk

  • GSTM1 null genotype
  • Sepsis post-HSCT
  • Age (age <2, older age)
  • Previous liver disease
  • Ferritin ≥950 ng/mL
  • Elevated AST/ALTb
  • High intensity/MAC regimens
  • GvHD prophylaxis
  • Horse ATG treatment
    (aplastic anemia)

1-3 times
greater risk

  • Inborn errors of metabolism
  • Leukemia diagnosis
  • Previous abdominal radiation
  • Impaired pulmonary function
  • KPS score <90%
  • ECOG PS 2-4
  • Advanced disease status
  • Elevated AST/ALTb
  • Hepatitis C
  • Previous HSCT
  • Allogeneic vs autologous HSCT
  • Unrelated/HLA mismatch
  • Total body irradiation
  • Early neutrophil engraftment

Previous inotuzumab or gemtuzumab use confers the highest level of risk among all reported VOD/SOS risk factors.8,11-14

aBased on odds ratio. Odds ratio represents the odds that a complication will occur if the risk factor is present, compared with the odds of the complication occurring if the risk factor is absent.14

bThe odds ratio for elevated AST/ALT ranges from 2.4 to 4.6.13

Patients treated with antibody drug conjugates (ADCs) are at high risk for VOD/SOS post HSCT

Incidence of VOD/SOS post HSCT following prior inotuzumab ozogamicin treatment15,16,c

INO-VATE ALL Phase 3 Clinical Study CIBMTR Registry Study
 

Incidence of VOD/SOS post HSCT following prior gemtuzumab ozogamicin treatment17,e

Restrospective Clinical Trial Analysis

Patients receiving HSCT following treatment with ADCs should be closely monitored for signs and symptoms of VOD/SOS.15,18

c In a Phase 3 multicenter, open‐label, randomized study that included 326 patients (inotuzumab ozogamicin [n=164] or investigator's choice of chemotherapy [n=162]) with relapsed or refractory ALL, 79 of whom received inotuzumab ozogamicin and subsequent allogeneic HSCT.15,19 Please refer to BESPONSA™ Prescribing Information for additional safety and efficacy data.

dData from a CIBMTR registry of US patients with ALL age ≥18 years old treated with inotuzumab ozogamicin, who proceeded to allogeneic HSCT, collected from August 2017 to August 2022.16

eIn the ALFA-0701 study, VOD events were reported in 5% (n=6/131) patients during or following treatment with gemtuzumab ozogamicin, or following subsequent HSCT.18 Please refer to MYLOTARG® Prescribing Information for additional safety and efficacy data.

fData reported in FDA database by academic pharmacovigilance initiative of adults with AML treated with gemtuzumab ozogamicin in clinical trials (n=162 patients), who proceeded to allogeneic HSCT.17

Explore the Defitelio MOA
Discover diagnostic criteria

IMPORTANT SAFETY INFORMATION AND INDICATION

Contraindications

Defitelio is contraindicated in the following conditions:

Indication

Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

IMPORTANT SAFETY INFORMATION

Contraindications

Defitelio is contraindicated in the following conditions:

  • Concomitant administration with systemic anticoagulant or fibrinolytic therapy
  • Known hypersensitivity to Defitelio or to any of its excipients

Indication

Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

IMPORTANT SAFETY INFORMATION

Contraindications

Defitelio is contraindicated in the following conditions:

  • Concomitant administration with systemic anticoagulant or fibrinolytic therapy
  • Known hypersensitivity to Defitelio or to any of its excipients

Warnings and Precautions

Hemorrhage

Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs, withhold or discontinue Defitelio.

Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects of the anticoagulant have abated.

Hypersensitivity Reactions

Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat according to the standard of care, and monitor until symptoms resolve.

Most Common Adverse Reactions

The most common adverse reactions (incidence ≥10% and independent of causality) with Defitelio treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.

Please see full Prescribing Information.

Indication

Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

IMPORTANT SAFETY INFORMATION

Contraindications

Defitelio is contraindicated in the following conditions:

  • Concomitant administration with systemic anticoagulant or fibrinolytic therapy
  • Known hypersensitivity to Defitelio or to any of its excipients

Warnings and Precautions

Hemorrhage

Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs, withhold or discontinue Defitelio.

Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects of the anticoagulant have abated.

Hypersensitivity Reactions

Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat according to the standard of care, and monitor until symptoms resolve.

Most Common Adverse Reactions

The most common adverse reactions (incidence ≥10% and independent of causality) with Defitelio treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.

Please see full Prescribing Information.

ALL=acute lymphoblastic leukemia; ALT=alanine aminotransferase; AML=acute myeloid leukemia; AST=aspartate aminotransferase; ATG=antithymocyte globulin; CIBMTR=Center for International Blood and Marrow Transplant Research; ECOG PS=Eastern Cooperative Oncology Group performance score; FDA=Food and Drug Administration; GSTMI=glutathione S-transferase mu 1; GvHD=graft-vs-host disease; HLA=human leukocyte antigen; HSCT=hematopoietic stem-cell transplantation; KPS=Karnofsky Performance Scale; MAC=myeloblative conditioning; MOA=mechanism of action; R/R=relapsed/refractory; SOS=sinusoidal obstruction syndrome; VOD=veno-occlusive disease.

References: 1. Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157-168. 2. Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2015;168(4):481-491. 3. Carreras E. Early complications after HSCT. In: Apperley J, Carreras E, Gluckman E, Masszi T, eds. The EBMT Handbook. 6th ed. Paris, France: European School of Haematology; 2012:176‐195. 4. Richardson PG, Ho VT, Cutler C, et al. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant. 2013;19(suppl 1):S88-S90. 5. Richardson PG, Corbacioglu S, Ho VT, et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013;12(1):123-136. 6. Vion AC, Rautou PE, Durand F, et al. Interplay of inflammation and endothelial dysfunction in bone marrow transplantation: focus on hepatic veno-occlusive disease. Semin Thromb Hemost. 2015;41(6):629-643. 7. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22(1):27-41. 8. Cairo MS, Cooke KR, Lazarus HM, Chao N. Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. Br J Haematol. 2020;190(6):822-836. 9. Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev. 2003;17(2):63-70. 10. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85(11):3005-3020. 11. Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906-912. 12. Corbacioglu S, Jabbour EJ, Mohty M. Risk factors for development of and progression of hepatic venoocclusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant. 2019;25(7):1271-1280. 13. Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22(3):400-409. 14. Szumilas, M. Explaining odds ratios. J Can Acad Child Adolesc Psychiatry. 2010;19(3):227-229. 15.  Besponsa [package insert]. New York, NY: Pfizer. 16. De Lima MJG, Kebriaei P, Lanza F, et al. A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT). Abstract presented at: European Hematology Association (EHA), June 9-17, 2021. Virtual congress. https://ascopubs.org/​doi/​abs/​10.1200/​JCO.2021.39.15_suppl.​7017 17. Magwood-Golston JS, Kessler S, Bennett CL. Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk Res. 2016;44:61-64. 18. Mylotarg [package insert]. New York, NY: Pfizer. 19. Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387-e398.